Does Worse Sleep Predict Greater Anxiety Improvement With Medical Cannabis?
Short answer: In a 302-patient registry cohort, worse baseline sleep was associated with a greater chance of meaningful improvement in anxiety scores during medical-cannabis treatment. After accounting for other variables, however, baseline sleep was not an independent predictor of the study’s clinically significant 12-month anxiety outcome. The design cannot prove that cannabis caused the changes.
Who was studied?
The study included patients treated for generalized anxiety disorder with cannabis-based medicinal products. Researchers compared those with and without comorbid sleep disturbance and followed patient-reported measures at baseline and at 1, 3, 6, and 12 months.
Outcomes included the seven-item Generalized Anxiety Disorder scale (GAD-7), a single-item sleep-quality scale, and health-related quality-of-life measures.
What did the researchers observe?
Across the cohort, anxiety, sleep, and several quality-of-life scores improved over time. Patients with worse sleep at baseline were more likely to show a meaningful GAD-7 improvement. In multivariable analysis, the type of cannabis product and baseline anxiety severity were associated with improvement, while baseline sleep quality did not independently predict the clinically significant 12-month endpoint.
The paper also reported that cannabis-naïve and former users had higher odds of an adverse event than current users. That association may reflect tolerance, selection, dosing, or other group differences; it does not isolate one mechanism.
Why the study cannot establish efficacy
The authors identified major limitations: it was an observational case series with no untreated or active comparator, no randomization, and no blinding. Participants were private medical-cannabis patients, many with prior cannabis experience. Other medications, unregulated cannabis use, expectations, regression to the mean, and loss to follow-up could influence patient-reported outcomes.
How should the finding be used?
The cohort helps generate questions for randomized trials: whether sleep disturbance identifies a subgroup with a different anxiety trajectory, which formulations and doses matter, and how prior cannabis exposure changes adverse-event risk. It should not be read as proof that medical cannabis treats anxiety or insomnia for a particular patient.
This article is educational and is not medical advice.
Source
Murphy M, et al. A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance. Neuropsychopharmacology Reports. 2024. PubMed record (PMID 38155535). DOI: 10.1002/npr2.12407.
